Cargando…

Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy

PURPOSE: Immune activation with T cell tumor infiltration is beneficial for the prognosis of patients suffering from solid cancer. Depending on their immune status, solid tumors can be immunologically classified into three groups: “hot” tumors are infiltrated with T lymphocytes, “cold” tumors are no...

Descripción completa

Detalles Bibliográficos
Autores principales: Mühlberger, Marina, Janko, Christina, Unterweger, Harald, Friedrich, Ralf P, Friedrich, Bernhard, Band, Julia, Cebulla, Nadine, Alexiou, Christoph, Dudziak, Diana, Lee, Geoffrey, Tietze, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817714/
https://www.ncbi.nlm.nih.gov/pubmed/31749616
http://dx.doi.org/10.2147/IJN.S218488
_version_ 1783463482072498176
author Mühlberger, Marina
Janko, Christina
Unterweger, Harald
Friedrich, Ralf P
Friedrich, Bernhard
Band, Julia
Cebulla, Nadine
Alexiou, Christoph
Dudziak, Diana
Lee, Geoffrey
Tietze, Rainer
author_facet Mühlberger, Marina
Janko, Christina
Unterweger, Harald
Friedrich, Ralf P
Friedrich, Bernhard
Band, Julia
Cebulla, Nadine
Alexiou, Christoph
Dudziak, Diana
Lee, Geoffrey
Tietze, Rainer
author_sort Mühlberger, Marina
collection PubMed
description PURPOSE: Immune activation with T cell tumor infiltration is beneficial for the prognosis of patients suffering from solid cancer. Depending on their immune status, solid tumors can be immunologically classified into three groups: “hot” tumors are infiltrated with T lymphocytes, “cold” tumors are not infiltrated and “immune excluded” tumors are only infiltrated in the peripheral tumor tissue. Checkpoint inhibitors provide new therapeutic options for “hot” tumors by triggering the immune response of T cells. In order to enable this for cold tumors as well, T cells must be enriched in the tumor. Therefore, we use the principle of magnetic targeting to guide T cells loaded with citrate-coated superparamagnetic iron oxide nanoparticles (SPION(Citrate)) to the tumor by an externally applied magnetic field. METHODS: SPION(Citrate) were produced by alkaline coprecipitation of iron(II) and iron(III) chloride and in situ coating with sodium citrate. The concentration-dependent cytocompatibility of the particles was determined by flow cytometry and blood stability assays. Atomic emission spectroscopy was used for the quantification of the particle uptake into T lymphocytes. The attractability of the loaded cells was observed by live-cell imaging in the presence of an externally applied magnetic field. RESULTS: SPION(Citrate) displayed good cytocompatibility to T cells and did not show any sign of aggregation in blood. Finally, SPION(Citrate)-loaded T cells were strongly attracted by a small external magnet. CONCLUSION: T cells can be “magnetized” by incorporation of SPION(Citrate) for magnetic targeting. The production of the particle-cell hybrid system is straightforward, as the loading process only requires basic laboratory devices and the loading efficiency is sufficient for cells being magnetically controllable. For these reasons, SPION(Citrate) are potential suitable candidates for magnetic T cell targeting.
format Online
Article
Text
id pubmed-6817714
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-68177142019-11-20 Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy Mühlberger, Marina Janko, Christina Unterweger, Harald Friedrich, Ralf P Friedrich, Bernhard Band, Julia Cebulla, Nadine Alexiou, Christoph Dudziak, Diana Lee, Geoffrey Tietze, Rainer Int J Nanomedicine Original Research PURPOSE: Immune activation with T cell tumor infiltration is beneficial for the prognosis of patients suffering from solid cancer. Depending on their immune status, solid tumors can be immunologically classified into three groups: “hot” tumors are infiltrated with T lymphocytes, “cold” tumors are not infiltrated and “immune excluded” tumors are only infiltrated in the peripheral tumor tissue. Checkpoint inhibitors provide new therapeutic options for “hot” tumors by triggering the immune response of T cells. In order to enable this for cold tumors as well, T cells must be enriched in the tumor. Therefore, we use the principle of magnetic targeting to guide T cells loaded with citrate-coated superparamagnetic iron oxide nanoparticles (SPION(Citrate)) to the tumor by an externally applied magnetic field. METHODS: SPION(Citrate) were produced by alkaline coprecipitation of iron(II) and iron(III) chloride and in situ coating with sodium citrate. The concentration-dependent cytocompatibility of the particles was determined by flow cytometry and blood stability assays. Atomic emission spectroscopy was used for the quantification of the particle uptake into T lymphocytes. The attractability of the loaded cells was observed by live-cell imaging in the presence of an externally applied magnetic field. RESULTS: SPION(Citrate) displayed good cytocompatibility to T cells and did not show any sign of aggregation in blood. Finally, SPION(Citrate)-loaded T cells were strongly attracted by a small external magnet. CONCLUSION: T cells can be “magnetized” by incorporation of SPION(Citrate) for magnetic targeting. The production of the particle-cell hybrid system is straightforward, as the loading process only requires basic laboratory devices and the loading efficiency is sufficient for cells being magnetically controllable. For these reasons, SPION(Citrate) are potential suitable candidates for magnetic T cell targeting. Dove 2019-10-24 /pmc/articles/PMC6817714/ /pubmed/31749616 http://dx.doi.org/10.2147/IJN.S218488 Text en © 2019 Mühlberger et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Mühlberger, Marina
Janko, Christina
Unterweger, Harald
Friedrich, Ralf P
Friedrich, Bernhard
Band, Julia
Cebulla, Nadine
Alexiou, Christoph
Dudziak, Diana
Lee, Geoffrey
Tietze, Rainer
Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy
title Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy
title_full Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy
title_fullStr Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy
title_full_unstemmed Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy
title_short Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy
title_sort functionalization of t lymphocytes with citrate-coated superparamagnetic iron oxide nanoparticles for magnetically controlled immune therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817714/
https://www.ncbi.nlm.nih.gov/pubmed/31749616
http://dx.doi.org/10.2147/IJN.S218488
work_keys_str_mv AT muhlbergermarina functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy
AT jankochristina functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy
AT unterwegerharald functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy
AT friedrichralfp functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy
AT friedrichbernhard functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy
AT bandjulia functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy
AT cebullanadine functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy
AT alexiouchristoph functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy
AT dudziakdiana functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy
AT leegeoffrey functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy
AT tietzerainer functionalizationoftlymphocyteswithcitratecoatedsuperparamagneticironoxidenanoparticlesformagneticallycontrolledimmunetherapy